KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin (2017 - 2026)

Aquestive Therapeutics has reported FCF Margin over the past 9 years, most recently at 61.81% for Q4 2025.

  • For Q4 2025, FCF Margin fell 768.0% year-over-year to 61.81%; the TTM value through Dec 2025 reached 117.82%, down 5556.0%, while the annual FY2025 figure was 117.82%, 5556.0% down from the prior year.
  • FCF Margin for Q4 2025 was 61.81% at Aquestive Therapeutics, up from 100.6% in the prior quarter.
  • Over five years, FCF Margin peaked at 79.16% in Q1 2023 and troughed at 269.9% in Q1 2025.
  • A 5-year average of 67.48% and a median of 73.21% in 2021 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: surged 192430bps in 2021 and later crashed -18350bps in 2025.
  • Year by year, FCF Margin stood at 77.58% in 2021, then surged by 201bps to 78.54% in 2022, then tumbled by -148bps to 37.54% in 2023, then tumbled by -44bps to 54.12% in 2024, then fell by -14bps to 61.81% in 2025.
  • Business Quant data shows FCF Margin for AQST at 61.81% in Q4 2025, 100.6% in Q3 2025, and 80.19% in Q2 2025.